Article Sidebar

PDF
Date Published: 20/07/2021
Abstract Views: 251
Views PDF: 150
DOI: https://doi.org/10.51298/vmj.v501i1.478
Issue
Vol. 501 No. 1 (2021)
Section
Các bài báo
How to Cite
Việt Hà, N. ., & Tuyết Mai, N. . (2021). TREATMENT RESULTS OF STAGE IIIB- IV NON-SMALL CELL LUNG CANCER WITH PEMETREXED - CISPLATIN REGIMEN. Vietnam Medical Journal, 501(1). https://doi.org/10.51298/vmj.v501i1.478

TREATMENT RESULTS OF STAGE IIIB- IV NON-SMALL CELL LUNG CANCER WITH PEMETREXED - CISPLATIN REGIMEN

Nguyễn Việt Hà, Nguyễn Tuyết Mai

Main Article Content

Abstract

Objects: Evaluating the initial treatment results and toxicity of regimen Pemetrexed and Cisplatin in lung cancer patients at stage IIIB and IV. Subjects and Methods: Uncontrolled clinical intervention on 56 lung cancer patients non-small cell at stage IIIB and IV. Results: After 6 cycles: partial response 22/56 (39,3%), stable disease 26/56 (46,4%), clinical benefits 85,7%. 06 patients drop leukocyte at level 3 and 4, accounted for 10.7% . Progresive Free Survival  6,1 ± 3,3month , Overall Survival   10,7 ± 4,1 month. Survival rates after 1 and 2 year were 42,4% and 17,5%. Conclusion: Regimen Pemetrexed – Cisplatin was well outcome and tolerated in non-small cell lung cancer patients at distant metastasis stage.

Article Details

Keywords

Non small cell lung cancer, Partial Response, Survival

References

1. GLOBOCAN (2012), "Etimated Cancer Incidence, Mortality and Prevalance Worldwide in 2012".
2. Bùi Diệu, Nguyễn Bá Đức, Trần Văn Thuấn, Nguyễn Thị Hoài Nga và cs (2012), "Gánh nặng bệnh ung thư và chiến lược phòng chống ung thư quốc gia đến năm 2020", Tạp chí Ung thư học Việt Nam, số 1 tr 13 - 19.
3. Nguyễn Bá Đức (2007), "Chẩn đoán và điều trị bệnh ung thư", Nhà xuất bản y hoc tr. 176 - 187.
4. Van Houtte P, McDonald S, Yuang-Chi Chang A, Salazar OM. Lung cancer 8 ed. In: Rubin P, Williams JP, editors. Clinical oncology: a multidisciplinary approach for physicians and students. Philadelphia, PA: WB Saunders Company; 2001
5. Schiller, J.H., et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002. 346(2): p. 92-8.
6. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21: 1556 –61
7. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma. Cancer 2001 ; 92: 595 –600.
8. Goldman DI, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002;29:3–17
9. Zinner RG, Obasaju CK, Fossella FV, et al. A phase II trial of ALIMTA plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) [abstract P-522]. Lung Cancer 2003 ; 41: S223